Chugai Seiyaku Kabushiki Kaisha

Sakae Takaku

Shigeyuki Kataoka

Minoru Shindo

Takashi Mori

Takashi Matsuno

Yasushi Murakami

Nobuhiro Oi

Kouji Furuno

Takeaki Hirano

Tamotsu Yamazaki

Toshichika Ogasawara

Shun-Ichi Hata

Shigeru Takanashi

Yukifumi Noda

Yasuhisa Takeda

Fumiaki Matsuura

Isao Matsunaga

Yasuhiro Yamashita

Yoshimitsu Iida

Kiyoshige Ochi

Hiroyuki Nagano

Koji Mizuno

Kazuo Igusa

Yoshiyuki Ohsugi

Mitsutaka Yoshida

Hiroshi Nakakimura

Kazuo Sasahara

Yasuo Fujimura

Yutaka Miura

Akira Okazaki

Tomohiro Neichi

Akiko Ariga

Yoshiyuki Osugi

Tatsuo Kujirai

Shigeru Sugano

Shogo Tomizawa

Mituo Shiratori

Yumiko Takeda

Shinichi Kaiho

This specification discloses a production process for an sucralfate aqueous suspension stock, the process being characterized by direct dispersement of an sucralfate aqueous stock for sucralfate preparations, which contains sucralfate particles with an average particle size of no more than 50 .mu.m in a concentration of 1-2 g/ml, in water or other aqueous medium without drying the synthesized sucralfate wet powder, followed by milling of the sucralfate particles to an average particle size of no more than 50 .mu.m. When the sucralfate aqueous suspension stock obtained directly from wet powder in accordance with this method is compared to the conventional suspension obtained from dry powder, equivalency of both stocks are obtained in terms of both properties and pharmacological activities. In comparison to the conventional process using dry powder, this wet milling method of production is economically and operationally superior and environmental pollution arising from the conventional process can be prevented.

Sucralfate aqueous suspension and its method of preparation

4-aminopyridine derivatives represented by the general formula: ##STR1## [wherein R.sub.1 is a hydrogen atom, a hydroxyl group, a linear or branched lower alkyl group or a cycloalkyl group which may be substituted by a hydroxyl group, a lower alkoxy group, a lower alkyl or a cycloalkyl group which contains a carbonyl group, a morpholino group or a group --NH--B (where B is a lower alkyl group, a cycloalkyl group or a phenyl group); R.sub.2 and R.sub.3 which may be the same or different each represents a hydrogen atom, a lower alkyl group or a loweralkylcarbonyl group, or when taken together, form an azacycloalkyl group, a morpholino group or an N-methylpiperazinyl group together with the nitrogen atom; R.sub.4 and R.sub.5 each represents a hydrogen atom, or when taken together with the ring A, form a quinoline ring or a 5,6,7,8-tetrahydroquinoline ring, provided that when each of R.sub.1, R.sub.4 and R.sub.5 is a hydrogen atom, R.sub.2 and R.sub.3 are neither a hydrogen atom nor a methyl group at the same time, and when R.sub.1 is a hydrogen atom and R.sub.4 and R.sub.5 taken together with the ring A form a quinoline ring, R.sub.2 and R.sub.3 are neither a hydrogen atom nor an ethyl group at the same time], and an acid addition salts of said 4-aminopyridine derivatives. These compounds are useful as active ingredients in pharmaceutical compositions for improving psychoneural function, especially in the treatment of Alzheimer type dementia and promotion of mnemonic and learning performance.

3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline

Novel compound, 1,2-bis(nicotinamido)propane and its pharmaceutically acceptable salts, a process for preparing the same and a pharmaceutical composition containing the same as an active ingredient are disclosed. The compound acts to prevent or spasmolyse cerebral vasospasms, to prevent cerebral apoplexy and to lower the lipoperoxide level in blood.

Nicotinamide derivative, process for preparing the same and

1,4,5,6-Tetrahydronicotinamide derivative represented by the formula: ##STR1## (wherein R is defined in the specification), a process of preparing the same and pharmaceutical composition containing the same are disclosed. The compound has action for suppressing aggregation of platelets, and antiinflammatory, antipyretic and analgesic actions.

Tetrahydronicotinamide derivative, pharmaceutical compositions and use

A terephthalic acid monoamide derivative of the formula: ##STR1## (wherein R is a straight- or branched-chain lower alkyl group; R' and R' may be the same or different, and represent a hydrogen atom, or a straight- or branched-chain lower alkyl group) or pharmaceutically acceptable salts thereof are disclosed. A process for preparing such terephthalic acid monoamide derivative or its salts, as well as an anti-allergic agent containing such derivative or its salts as an effective ingredient are also disclosed.

Terephthalic acid monoamide derivatives, process for preparing the same,

A compound of the formula ##STR1## is useful for treating circulatory diseases.

Nitric ester of N-(2-hydroxyethyl)nicotinamide and pharmaceutical use

A pharmaceutical composition for prevention and treatment of gastritis and peptic ulcer of mammals including human beings which contains a bis(benzamido)benzene derivative represented by the formula ##STR1## wherein X and Y are as defined hereinbelow, or an acid addition salt thereof, as an active ingredient, and a method of the use thereof are disclosed.

Pharmaceutical composition and method of the use thereof

Bis(benzamido)-benzene derivatives having various pharmaceutical activities such as activity for preventing and treating peptic ulcer, peripheral vasodilating action, hypotensive activity and analgesic activity and represented by the formula ##STR1## wherein X, Y, Z, R.sub.1, R.sub.2 and R.sub.3 are as defined hereinafter and a process for preparing the same are disclosed.

Bis(benzamido)-benzene derivatives

A pharmaceutical composition for prevention and treatment of gastritis and peptic ulcer of mammals including human beings which contains a bis(benzamido)-benzene derivative represented by the formula ##STR1## wherein X and Y are as defined hereinbelow or an acid addition salt thereof as an active ingredient, and a method of the use thereof are disclosed.

A bis(benzamido)-benzoic acid derivative represented by the formula ##SPC1## Wherein R.sup.1, R.sup.2 and R.sup.3 are as defined hereinbelow and a process for preparing the same is disclosed. The compounds of the invention inhibit hemolysis of sheep red blood cell and cutaneous anaphylactic reaction, and also have an antipyretic sedative, anti-inflammatory and anti-allergic effect and are especially useful for treatment of rheumatic arthritis, bronchial asthma and nephritis.

Bis(benzamido)-benzoic acid derivatives

Growing community of inventors

Ageo, Japan

Sakae Takaku